175 related articles for article (PubMed ID: 22223822)
1. Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman disease.
Gérard L; Michot JM; Burcheri S; Fieschi C; Longuet P; Delcey V; Meignin V; Agbalika F; Chevret S; Oksenhendler E; Galicier L
Blood; 2012 Mar; 119(10):2228-33. PubMed ID: 22223822
[TBL] [Abstract][Full Text] [Related]
2. Characteristics and survival for HIV-associated multicentric Castleman disease in Malawi.
Gopal S; Liomba NG; Montgomery ND; Moses A; Kaimila B; Nyasosela R; Chikasema M; Dhungel BM; Kampani C; Sanders MK; Krysiak R; Dittmer DP; Fedoriw Y
J Int AIDS Soc; 2015; 18(1):20122. PubMed ID: 26242311
[TBL] [Abstract][Full Text] [Related]
3. Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease.
Hoffmann C; Schmid H; Müller M; Teutsch C; van Lunzen J; Esser S; Wolf T; Wyen C; Sabranski M; Horst HA; Reuter S; Vogel M; Jäger H; Bogner J; Arasteh K
Blood; 2011 Sep; 118(13):3499-503. PubMed ID: 21778341
[TBL] [Abstract][Full Text] [Related]
4. Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease.
Uldrick TS; Polizzotto MN; Aleman K; Wyvill KM; Marshall V; Whitby D; Wang V; Pittaluga S; O'Mahony D; Steinberg SM; Little RF; Yarchoan R
Blood; 2014 Dec; 124(24):3544-52. PubMed ID: 25331113
[TBL] [Abstract][Full Text] [Related]
5. High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease.
Oksenhendler E; Boulanger E; Galicier L; Du MQ; Dupin N; Diss TC; Hamoudi R; Daniel MT; Agbalika F; Boshoff C; Clauvel JP; Isaacson PG; Meignin V
Blood; 2002 Apr; 99(7):2331-6. PubMed ID: 11895764
[TBL] [Abstract][Full Text] [Related]
6. Brief communication: rituximab in HIV-associated multicentric Castleman disease.
Bower M; Powles T; Williams S; Davis TN; Atkins M; Montoto S; Orkin C; Webb A; Fisher M; Nelson M; Gazzard B; Stebbing J; Kelleher P
Ann Intern Med; 2007 Dec; 147(12):836-9. PubMed ID: 18087054
[TBL] [Abstract][Full Text] [Related]
7. Treatment of multicentric Castleman’s disease in HIV-1 infected and uninfected patients: a systematic review.
Rokx C; Rijnders BJ; van Laar JA
Neth J Med; 2015 Jun; 73(5):202-10. PubMed ID: 26087799
[TBL] [Abstract][Full Text] [Related]
8. Relapse of HHV8-positive multicentric Castleman disease following rituximab-based therapy in HIV-positive patients.
Pria AD; Pinato D; Roe J; Naresh K; Nelson M; Bower M
Blood; 2017 Apr; 129(15):2143-2147. PubMed ID: 28143881
[TBL] [Abstract][Full Text] [Related]
9. Clinical use of rituximab in patients with HIV related lymphoma and Multicentric Castleman's disease.
Reid E; Nooka A; Blackmon J; Lechowicz MJ
Curr Drug Deliv; 2012 Jan; 9(1):41-51. PubMed ID: 22023215
[TBL] [Abstract][Full Text] [Related]
10. Higher rate of progression in HIV- than in HIV+ patients after rituximab for HHV8+ multicentric Castleman disease.
Rasmussen C; Gérard L; Fadlallah J; Corvilain E; Galicier L; Meignin V; Oksenhendler E; Boutboul D
Blood Adv; 2023 Sep; 7(18):5663-5669. PubMed ID: 37288720
[TBL] [Abstract][Full Text] [Related]
11. How I treat HIV-associated multicentric Castleman disease.
Bower M
Blood; 2010 Nov; 116(22):4415-21. PubMed ID: 20688959
[TBL] [Abstract][Full Text] [Related]
12. HHV8-positive, HIV-negative multicentric Castleman's disease: early and sustained complete remission with rituximab therapy without reactivation of Kaposi sarcoma.
Nicoli P; Familiari U; Bosa M; Allice T; Mete F; Morotti A; Cilloni D; Saglio G; Guerrasio A
Int J Hematol; 2009 Oct; 90(3):392-396. PubMed ID: 19756920
[TBL] [Abstract][Full Text] [Related]
13. Cytokine changes during rituximab therapy in HIV-associated multicentric Castleman disease.
Bower M; Veraitch O; Szydlo R; Charles P; Kelleher P; Gazzard B; Nelson M; Stebbing J
Blood; 2009 May; 113(19):4521-4. PubMed ID: 19224759
[TBL] [Abstract][Full Text] [Related]
14. Rituximab therapy for HIV-associated Castleman disease.
Marcelin AG; Aaron L; Mateus C; Gyan E; Gorin I; Viard JP; Calvez V; Dupin N
Blood; 2003 Oct; 102(8):2786-8. PubMed ID: 12842986
[TBL] [Abstract][Full Text] [Related]
15. Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease.
Powles T; Stebbing J; Montoto S; Nelson M; Gazzard B; Orkin C; Webb A; Bower M
Blood; 2007 Dec; 110(12):4132-3. PubMed ID: 18024800
[No Abstract] [Full Text] [Related]
16. [Two HHV8-related illnesses in a HIV-negative patient: Kaposi's sarcoma and multicentric Castleman's disease. Response to treatment with Rituximab and CHOP].
Pastor MA; Vasco B; Mosquera JM; Debén G; Bautista P; Requena L
Actas Dermosifiliogr; 2006; 97(6):385-90. PubMed ID: 16956518
[TBL] [Abstract][Full Text] [Related]
17. Clinical dissection of multicentric Castleman disease.
Shin DY; Jeon YK; Hong YS; Kim TM; Lee SH; Kim DW; Kim I; Yoon SS; Heo DS; Park S; Kim BK
Leuk Lymphoma; 2011 Aug; 52(8):1517-22. PubMed ID: 21585280
[TBL] [Abstract][Full Text] [Related]
18. Coexistence of disseminated Kaposi sarcoma and multicentric Castleman disease in an HIV-infected patient under viral suppression.
Lin IF; Lin JN; Tsai TH; Hsu CT; Wu YY; Lai CH
Int J STD AIDS; 2021 Mar; 32(3):286-289. PubMed ID: 33555231
[TBL] [Abstract][Full Text] [Related]
19. Development of Kaposi's sarcoma after complete remission of multicentric Castlemans disease with rituximab therapy in a HHV8-positive, HIV-negative patient.
Law AB; Ryan G; Lade S; Prince HM
Int J Hematol; 2010 Mar; 91(2):347-8; author reply 349. PubMed ID: 20146033
[No Abstract] [Full Text] [Related]
20. Characteristics and outcomes of KSHV-associated multicentric Castleman disease with or without other KSHV diseases.
Ramaswami R; Lurain K; Polizzotto MN; Ekwede I; Waldon K; Steinberg SM; Mangusan R; Widell A; Rupert A; George J; Gonçalves PH; Marshall VA; Whitby D; Wang HW; Pittaluga S; Jaffe ES; Little RF; Uldrick TS; Yarchoan R
Blood Adv; 2021 Mar; 5(6):1660-1670. PubMed ID: 33720337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
